USAEUROPEViVE
ABOUTSPONSORSHIPFOUNDATION
Logo Hlth
Logo Hlth
21 Feb 2023 | 03:45 PM GMT

Standards for Robust Evidence from Digital Health in Oncology

Anchored by:

Simon Spahrkäs
Head of Research
TIRED OF CANCER B.V.

Participants:

Simon Spahrkäs Head of ResearchTired of Cancer B.V.
Simon Spahrkäs
Head of ResearchTired of Cancer B.V.
Chandana Fitzgerald President, CommunityHLTH
Chandana Fitzgerald
President, CommunityHLTH
Alex Holroyd-Smith Head of Business DevelopmentAlvie Health
Alex Holroyd-Smith
Head of Business DevelopmentAlvie Health
Bert Hartog R&D OperationsThe Janssen Pharmaceutical Companies of Johnson & Johnson
Bert Hartog
R&D OperationsThe Janssen Pharmaceutical Companies of Johnson & Johnson
Cici Ceralde Director of Venture InsightsMcKesson
Cici Ceralde
Director of Venture InsightsMcKesson
HM
Hector Mateo Carrasco Medical AdvisorAccord Healthcare
HM
Hector Mateo Carrasco
Medical AdvisorAccord Healthcare
Judit Faus Innovation ManagerGrupo DKV
Judit Faus
Innovation ManagerGrupo DKV
Justin Norden PartnerGSR Ventures
Justin Norden
PartnerGSR Ventures
Lochlann McCabe Account Manager - BiopharmaVWR, part of Avantor
Lochlann McCabe
Account Manager - BiopharmaVWR, part of Avantor
Maggie O'Donovan Senior Consultant, Advisory and InsightsHLTH Inc
Maggie O'Donovan
Senior Consultant, Advisory and InsightsHLTH Inc
Marenne Hoogenboom Market Access ManagerOmnigen BV
Marenne Hoogenboom
Market Access ManagerOmnigen BV
Tessy Huss Director of Strategy , HLTH CommunityHLTH Community
Tessy Huss
Director of Strategy , HLTH CommunityHLTH Community
Timothy Graham Director Digital StrategyGSK
Timothy Graham
Director Digital StrategyGSK

About this Meeting

Small, intimate and participant-led discussions tackling digital health challenges. Spaces are limited to 8 - 12 people, allowing you to focus on quality in-depth conversations.

Due to the lack of industry-wide evidence frameworks  for digital health solutions in oncology, regulators’ and payers' requirements are usually the same as drugs. However, drugs and oncology digital health solutions are very different in nature, and it is hard to fit those digital solutions into the traditional evidence standards. On top of that, digital health companies have limited resources (money, time and people), which can get in the way of building more robust evidence. 

How can the industry incentivize the generation of more robust evidence? What should the standards be for digital health in oncology? Join this meeting to have a deeper conversation about:  

  • How can the industry work together to build clear standards that facilitate the generation of more robust evidence? What does good quality evidence look like for digital health in oncology?   
  • How would those new standards change across different countries? Should the oncology standards be different from other therapeutic areas? How to ensure all the stakeholders use them?  
  • How can small companies with limited resources build more robust evidence? Is having more robust evidence a must to be successful? What are the incentives?  
  • Is partnering a good strategy for digital health start-ups to build the evidence needed?  
  • How can companies build an evidence base that is robust but also flexible enough to satisfy both payers and regulators in a cost-effective manner?
We would like to remind you that our meetings are small and intimate sessions with a limited number of seats available, therefore we rely on your attendance and participation to ensure a high quality and valuable meeting for all. If you are confirmed for this meeting we ask if you can please ensure your attendance on the day.